@article{7f4f37c012d34444aa9062a5b24166f6,
title = "Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial",
author = "Sharman, \{Jeff P.\} and Farber, \{Charles M.\} and Daruka Mahadevan and Schreeder, \{Marshall T.\} and Brooks, \{Heather D.\} and Kolibaba, \{Kathryn S.\} and Fanning, \{Suzanne R.\} and Klein, \{Leonard M.\} and Peter Sportelli and Miskin, \{Hari P.\} and Weiss, \{Michael S.\} and Greenwald, \{Daniel R.\}",
note = "624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III | Kathryn Kolibaba, John M. Burke, Heather D. Brooks, Daruka Mahadevan, Jason Melear, Charles M. Farber, Suzanne R. Fanning, Marshall T. Schreeder, Ralph V. Boccia, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jeff P.",
year = "2014",
month = dec,
day = "6",
doi = "10.1182/BLOOD.V124.21.4679.4679",
language = "American English",
volume = "124",
journal = "Blood",
publisher = "American Society of Hematology",
number = "21",
}